Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | CCKBR | P32239 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31122188 | 1.00 | PGR (0.46) | PGRHTR2CCYP46A1NR3C1NR1I2 | |
| Hydrochloric Acid SCHEMBL10917557 | 0.99 | PGR (0.45) | PGRHTR2CCYP46A1NR3C1NR1I2 | |
| SCHEMBL18797014 | 0.92 | PGR (0.44) | PGRHTR2CCYP46A1NR3C1NR1I2 | |
| SCHEMBL17205437 | 0.92 | PGR (0.44) | PGRHTR2CCYP46A1NR3C1NR1I2 | |
| Hydrochloric Acid SCHEMBL18797045 | 0.90 | PGR (0.43) | PGRHTR2CCYP46A1NR3C1NR1I2 | |
| Hydrochloric Acid SCHEMBL17205976 | 0.90 | PGR (0.43) | PGRHTR2CCYP46A1NR3C1NR1I2 | |
| SCHEMBL4167455 | 0.88 | PDE7A (0.49) | PGRHTR2CCYP46A1NR3C1NR1I2 | |
| SCHEMBL7747427 | 0.85 | PGR (0.46) | PGRHTR2CCYP46A1NR3C1NR1I2 | |
| SCHEMBL17202823 | 0.83 | PDE7A (0.43) | PGRHTR2CCYP46A1NR3C1NR1I2 | |
| Hydrochloric Acid SCHEMBL17205486 | 0.82 | PDE7A (0.42) | PGRHTR2CCYP46A1NR3C1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428049-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190016701-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-9951046-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951046-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1688418-A2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-6436962-B1 | ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS; RELIEF FROM BENIGN PROSTATIC HYPERPLASIA BY LESS HINDERED URINE FLOW BY RELAXING SMOOTH MUSCLE TISSUE; WITH A TESTOSTERONE 5-ALPHA REDUCTASE INHIBITOR, FINASTERIDE; ACUTE AND CHRONIC RELIEF | MERCK & CO., INC. | 2002-08-20 | — | — | US | disclosed |
| US-6316437-B1 | ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001022919-A2 | SPIRO[BICYCLIC -AZACYCLOALKYL AND -CYCLOALKYL] DERIVATIVES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-0070171-B1 | NOVEL PIPERIDINE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | KYOWA HAKKO KOGYO CO., LTD (JP) | 1986-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428049-B2 | TRPA1 modulators | TRPA1, TRPV1, TRPV2 | PGR 3776/4885HTR2C 75/4885CYP46A1 4039/4885 |
| US-20190016701-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | PGR 3776/4885HTR2C 75/4885CYP46A1 4039/4885 |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | PGR 3121/4885HTR2C 3111/4885CYP46A1 970/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | PGR 3121/4885HTR2C 3111/4885CYP46A1 970/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | PGR 2938/4885HTR2C 3346/4885CYP46A1 404/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | PGR 3121/4885HTR2C 3111/4885CYP46A1 970/4885 |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | AVPR2, OXTR, AVPR1A | PGR 209/4885HTR2C 18/4885CYP46A1 1173/4885 |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | PGR 3152/4885HTR2C 1370/4885CYP46A1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.